Business / Finance

RSS

GenoSpace completes financing deal with Thomson Reuters

GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it completed a financing deal with Thomson Reuters, the world leader in providing intelligent information for businesses and professionals.

12 Aug 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

Valeant receives request for additional information from FTC under Hart-Scott-Rodino

Valeant Pharmaceuticals International, Inc. announced that the Company has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Valeant's proposed acquisition of Allergan, Inc.

12 Aug 2014

BIOREM announces 4 new orders totalling $1.5 million

BIOREM Inc. today announced four new orders totalling $1.5 million. The orders include a biogas conditioning system and an odour control system in North America, as well as an industrial VOC/odour abatement system in Asia and a small odour control system in the Middle East.

12 Aug 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA.

11 Aug 2014

MCMC announces sale of MCRS program business to PCM

MCMC LLC is pleased to announce the strategic sale of its Managed Care Risk Services program business to Patriot Care Management, Inc., an affiliate of Patriot National Insurance Group.

11 Aug 2014

Cardiome Pharma reports record revenues in second quarter 2014

Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2014.

11 Aug 2014

Roka Bioscience reports increased revenue of $1.4M with 107% year-over-year growth

Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today reported its financial results for the three and six months ended June 30, 2014.

11 Aug 2014

Dynatronics completes $3.8M sale and leaseback of its Utah facility

Dynatronics Corporation (NASDAQ: DYNT) today announced the completion of a $3.8 million sale and leaseback of its facility in Cottonwood Heights, UT. The purchaser was AIC Ventures of Austin, Texas.

11 Aug 2014

Forward Pharma files Form F-1 registration statement for initial public offering of shares

Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares.

11 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Chindex revenues increase 21% to $55.5M in second quarter 2014

Chindex International, Inc., an American healthcare company providing premium quality healthcare services in China through the operations of United Family Healthcare ("UFH"), a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the second quarter ended June 30, 2014.

11 Aug 2014

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.

11 Aug 2014

Bio-Techne revenue increases 16% to $92.5 million in fourth quarter 2014

Techne Corporation, (d/b/a Bio-Techne) today reported its financial results for the fourth quarter and full year ended June 30, 2014.

From ProteinSimple 11 Aug 2014

KFH/HP reports total operating revenue of $14 billion for second quarter 2014

Kaiser Foundation Hospitals, Kaiser Foundation Health Plan, Inc., and their respective subsidiaries reported today a combined total operating revenue of $14.0 billion for the quarter ending June 30, 2014, compared to $13.3 billion in the same period in 2013.

8 Aug 2014

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals plc today announced that Jazz Investments I Limited, its wholly-owned subsidiary, priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021.

8 Aug 2014

NxStage Medical reports record revenues for Q2 2014

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported second quarter revenue that exceeds the top end of its guidance range.

7 Aug 2014